The American pharmaceutical company Gilead and the Japanese company Eisai have concluded a distribution and marketing agreement for the drug filgotinib for the treatment of rheumatism in Japan. Financial details were not provided.
Gilead is responsible for the production and market approval of filgotinib. Eisai is going to distribute the drug. Gilead is the cooperation partner of the biotechnologist Galapagos, listed on the stock exchange in Amsterdam. The two previously signed a deal about the development and marketing of filgotinib.
Peretz M. is an accomplished economist and financial journalist with a deep understanding of the global economy and financial markets. He is a regular contributor to EconomicInform, where he provides expert analysis and commentary on current economic trends and events. With a strong educational background in economics, Peretz has a talent for breaking down complex economic concepts for a general audience and is able to provide insightful perspectives on a wide range of economic issues.